Regulatory Replimune rebounds to win FDA approval of melanoma drug BioPharma DiveThe accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists.OncologyRead full story pharminent August 6, 2026 (Last updated: August 8, 2026) BioPharma Dive The accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA Approves Moderna’s mFlusiva, the First mRNA-Based Seasonal Flu VaccineNext: Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments Related Stories Regulatory Takeda’s first-in-class narcolepsy drug claims FDA approval pharminent August 6, 2026 Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026
